Skip to main content
Premium Trial:

Request an Annual Quote

GenScript, Allozymes Partner on Enzyme Discovery and Development Services

NEW YORK – GenScript and Allozymes said on Wednesday that they are partnering on providing services to customers, including enzyme discovery, enzyme development, and protein identification.

Under the terms of the agreement, GenScript will provide mutant synthetic DNA libraries and protein expression while Allozymes will offer high-throughput screening services. Applications will include services for the pharmaceutical, cosmetic, and food and beverage industries.

Financial and other terms of the deal were not disclosed.

"Our relationship with Allozymes spans several years, and we are glad to expand this relationship to be an exclusive partner that provides researchers with a full suite of services, from discovery to expression of target molecules," said Dawn Lee, a sales director at GenScript Asia Pacific.

Singapore-based Allozymes offers droplet microfluidics-based enzyme screening and enzyme development services.

DNA synthesis is one of many services GenScript offers. In September, the firm partnered with Avectas on cell therapy manufacturing and, in April, it entered the DNA-based data storage market.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.